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Background
The two major melanoma histologic subtypes, superfi-
cial spreading and nodular melanomas, are believed to
differ in their speed of dermal invasion but to converge
biologically once they invade and metastasize. Here, we
tested the hypothesis that distinct molecular alterations
arising in primary melanoma cells might persist as these
tumors progress to invasion and metastasis.
Materials and methods
Expression of 141 signaling proteins was evaluated by
protein pathway array in 3 Radial Growth Phase (RGP)/
SSM and 3 Vertical Growth Phase (VGP)/NM cell lines.
The impact of p90-ribosomal-S6-kinase (RSK1) and its
inhibition on proliferation, migration and invasion was
assessed in SSM and NM cell lines, and confirmed using
NM cells treated with a RSK inhibitor (BI-D1870) in
microarray profiling studies. The effect of constitutive
RSK1 activation in vivo was further studied using a zeb-
rafish model.
Results
We show that p90-ribosomal-S6-kinase (RSK1) was sig-
nificantly hyper-activated in human melanoma lines and
metastatic tissues derived from nodular compared with
superficial spreading melanoma. RSK1 was constitutively
phosphorylated at Ser-380 in nodular but not superficial
spreading melanoma and was not directly correlated with
BRAF or MEK activation. Nodular melanoma cells were
more sensitive to RSK1 inhibition using both siRNA and
pharmacological inhibitor BI-D1870 compared with
superficial spreading cells. In addition, gene expression
microarray analyses revealed that RSK1 orchestrates a
program of gene expression that promotes cell motility
and invasion. Our data also demonstrate a differential
overexpression of the pro- metastatic MMP-8 and
TIMP-1 in metastatic nodular compared to metastatic
superficial spreading melanoma. Finally, using an in vivo
zebrafish model, constitutive RSK1 activation increased
melanoma invasion.
Conclusions
Together, our data reveal a novel role for activated RSK1
in the progression of nodular melanoma, and suggest that
melanoma originating from different histological subtypes
may be biologically distinct and that these differences are
maintained as the tumors invade and metastasize.
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